Dimethyloxalylglycine may be enhance the capacity of neural-like cells in treatment of Alzheimer disease.
OA: closed
AI-generated summary
Dimethyloxalylglycine enhances the capacity of neural-like cells derived from mesenchymal stem cells and improves their viability when transplanted into the brains of Alzheimer disease rats.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Although using differentiated stem cells is the best proposed option for the treatment of Alzheimer disease (AD), an efficient differentiation and cell therapy require enhanced cell survival and homing and decreased apoptosis. It seems that hypoxia preconditioning via Dimethyloxalylglycine (DMOG) may increase the capacity of MSC to induce neural like stem cells (NSCs). Furthermore, it can likely improve the viability of NSCs when transplanted into the brain of AD rats.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-10-04T09:26:46.659050+00:00
- unpaywall
- last seen: 2026-10-05T06:32:29.880811+00:00